Key Takeaways AMGN's Imdelltra cut death risk by 40% and extended median OS by 5.3 months vs. standard chemo. The DeLLphi-304 study showed median OS of 13.6 months for Imdelltra vs. 8.3 months for control. Imdelltra also improved PFS, symptom relief, and was well-tolerated with mostly mild to moderate side effects.Amgen (AMGN) announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra (tarlatamab-dlle) for treating patients with small cell lung cancer (SCL ...